Callan Capital LLC Purchases 108 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Callan Capital LLC lifted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,440 shares of the pharmaceutical company’s stock after buying an additional 108 shares during the period. Callan Capital LLC’s holdings in Vertex Pharmaceuticals were worth $2,081,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in VRTX. Davidson Capital Management Inc. increased its holdings in shares of Vertex Pharmaceuticals by 23.8% in the 2nd quarter. Davidson Capital Management Inc. now owns 7,205 shares of the pharmaceutical company’s stock worth $3,377,000 after purchasing an additional 1,383 shares in the last quarter. Joseph Group Capital Management lifted its stake in Vertex Pharmaceuticals by 9.7% during the 2nd quarter. Joseph Group Capital Management now owns 4,817 shares of the pharmaceutical company’s stock valued at $2,258,000 after acquiring an additional 426 shares during the period. Benjamin F. Edwards & Company Inc. boosted its holdings in shares of Vertex Pharmaceuticals by 18.8% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 5,892 shares of the pharmaceutical company’s stock valued at $2,761,000 after acquiring an additional 932 shares during the last quarter. Ieq Capital LLC boosted its holdings in Vertex Pharmaceuticals by 9.8% in the second quarter. Ieq Capital LLC now owns 21,093 shares of the pharmaceutical company’s stock worth $9,887,000 after purchasing an additional 1,877 shares during the last quarter. Finally, Brighton Jones LLC raised its stake in Vertex Pharmaceuticals by 280.9% during the 2nd quarter. Brighton Jones LLC now owns 4,300 shares of the pharmaceutical company’s stock valued at $2,015,000 after buying an additional 3,171 shares during the last quarter. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Up 0.8 %

Shares of NASDAQ:VRTX opened at $477.90 on Friday. Vertex Pharmaceuticals Incorporated has a 52-week low of $341.85 and a 52-week high of $510.64. The stock has a market cap of $123.32 billion, a P/E ratio of 31.01 and a beta of 0.40. The business’s 50 day moving average is $483.14 and its 200 day moving average is $451.58. The company has a quick ratio of 2.26, a current ratio of 2.52 and a debt-to-equity ratio of 0.02.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share for the quarter, missing the consensus estimate of ($12.54) by ($0.29). Vertex Pharmaceuticals had a negative net margin of 4.74% and a negative return on equity of 2.45%. The firm had revenue of $2.65 billion during the quarter, compared to the consensus estimate of $2.66 billion. During the same quarter in the previous year, the firm earned $3.53 earnings per share. The business’s revenue was up 6.1% compared to the same quarter last year. Sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post -2.14 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on VRTX shares. StockNews.com downgraded Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 5th. Wells Fargo & Company raised their price objective on shares of Vertex Pharmaceuticals from $540.00 to $555.00 and gave the stock an “overweight” rating in a report on Monday, June 24th. Guggenheim increased their price target on shares of Vertex Pharmaceuticals from $450.00 to $558.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. JPMorgan Chase & Co. boosted their price objective on shares of Vertex Pharmaceuticals from $505.00 to $510.00 and gave the company an “overweight” rating in a research report on Monday, August 5th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $480.00 target price on shares of Vertex Pharmaceuticals in a research report on Friday, August 2nd. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $486.36.

Insider Activity at Vertex Pharmaceuticals

In other news, CEO Reshma Kewalramani sold 15,202 shares of Vertex Pharmaceuticals stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $497.00, for a total value of $7,555,394.00. Following the transaction, the chief executive officer now directly owns 106,172 shares in the company, valued at approximately $52,767,484. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CMO Carmen Bozic sold 2,280 shares of the stock in a transaction on Wednesday, June 26th. The stock was sold at an average price of $471.72, for a total transaction of $1,075,521.60. Following the completion of the sale, the chief marketing officer now owns 30,099 shares in the company, valued at approximately $14,198,300.28. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Reshma Kewalramani sold 15,202 shares of the firm’s stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $497.00, for a total value of $7,555,394.00. Following the completion of the sale, the chief executive officer now directly owns 106,172 shares of the company’s stock, valued at approximately $52,767,484. The disclosure for this sale can be found here. Insiders have sold a total of 34,047 shares of company stock valued at $16,843,806 over the last ninety days. 0.20% of the stock is owned by company insiders.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.